Pulmonary fibrosis
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- Chronic progressive interstitial lung disorder characterized by the replacement of the lung tissue by connective tissue, leading to progressive dyspnea, respiratory failure, or right heart failure. Causes include chronic inflammatory processes, exposure to environmental irritants, radiation therapy, autoimmune disorders, certain drugs, or it may be idiopathic (no identifiable cause).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Pulmonary fibrosis
- Therapeutic area
- Pulmonology
- pulmonary fibrosis
- pulmonary interstitial fibrosis
- All therapeutic areas
- Pulmonology
- Severity
- Severe
- MONDO ID
- MONDO:0002771
- Parent condition
- MONDO:0015925
Related records
Broader conditions (7)
- Disease
- Disease by body system or component
- Human disease
- Interstitial lung disease
- Lower respiratory tract disorder
- Lung disorder
- Respiratory system disorder
Narrower conditions (15)
- Diffuse pulmonary fibrosis
- Graphite pneumoconiosis
- Localized pulmonary fibrosis
- Postinflammatory pulmonary fibrosis
- Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 7
- Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 8
- Pulmonary fibrosis and/or bone marrow failure syndrome, telomere-related, 9
- Pulmonary fibrosis and/or bone marrow failure, telomere-related
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 2
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 3
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 4
- Pulmonary fibrosis and/or bone marrow failure, telomere-related, 5
- Pulmonary fibrosis and/or bone marrow failure, telomere-related, 6
- Tuberculous fibrosis of lung
Trials (347)
- 23andMe IPF Research Study
- 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis
- 68Ga-FAPI PET/CT to Detect Ongoing Fibroblast Activity in Post-acute COVID-19
- 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
- 99mTc-HFAPI SPECT/CT in Pulmonary Fibrosis
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
- A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis
- A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
- A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
- A Non-pharmacological Cough Control Therapy
- A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
- A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis
- A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
- A Prospective, Multi-Center Registry Study of Progressive Pulmonary Fibrosis (PPF) in China (PROFINA)
- A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
- A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone
Approved drugs (1)
- Prednisolone sodium phosphate
Drugs in development (27)
- Acetylcysteine Phase 3
- Admilparant Phase 3
- Allyl isothiocyanate Phase 1
- Axatilimab Phase 1
- Azathioprine Phase 3
- Bevacizumab Phase 2
- Bexotegrast Phase 1
- Carlumab Phase 2
- CC-90001 Phase 1
- Cyclophosphamide Phase 3
- Dapsone Phase 2
- Dexamethasone Phase 2
- Dichloroacetic acid Phase 1
- Etanercept Phase 2
- Genistein Phase 2
- Interferon alfa Phase 2
- Interferon gamma-1B Phase 3
- Nintedanib Phase 3
- Oxygen Phase 2
- Pirfenidone Phase 2
Other linked drugs (3)
- Ciglitazone
- Deupirfenidone
- Pirinixic acid